Clinical trials: Psychotic Symptoms
Schizophrenia, Schizoaffective Disorders
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
This study involves people with schizophrenia or schizoaffective disorder, who are currently taking antipsychotic medications. Some antipsychotic medications may cause an increase in cholesterol levels, which may lead to…
- Conditions
- Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders
- Trial name
- NCT01082588
- Testing
- Pravastatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia
The purpose of this study is to compare efficacy and safety of add-on treatment with a moderately high dose of D-serine, an NMDA-glycine site agonist, in young, recent onset schizophrenia patients who suffer from significant…
- Trial name
- SATROS (NCT01459029)
- Testing
- D-serine
- Where
- 2 sites in Israel
- Volunteers
- 54 people
- Sponsor
- Hadassah Medical Organization
Healthy Control Subjects, Schizophrenia Diagnosis
Understanding Lifespan Trajectories of Social Cognition, Brain Microstructure and Iron Dysregulation in Schizophrenia
This study aims to better understand how schizophrenia may affect social thinking, emotion regulation, brain function, and biological processes over time. Two groups will take part in the study: 1.
- Trial name
- NCT07856381
- Where
- Austria
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Dementia, Depression
Geriatric Psychiatry and Pharmacovigilance
The purpose of this observational multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients.
- Conditions
- Dementia, Depression, Schizophrenia, Psychosomatic Disorders
- Trial name
- GAP (NCT01858857)
- Where
- 5 sites in Germany
- Volunteers
- 4,000 people
- Sponsor
- Hannover Medical School
Schizophrenia, Negative Symptoms in Schizophrenia
Dance and Movement Therapy in Patients With Schizophrenia
Introduction: Schizophrenia is a mental disorder that starts at a young age and progresses with positive (hallucination, delusion) and negative (decreased emotional participation, reluctance) symptoms.
- Conditions
- Schizophrenia, Negative Symptoms in Schizophrenia, Disabilities Mental, Dance Therapy
- Trial name
- DMTinSchizo (NCT05500651)
- Testing
- Dance and Movement Therapy (DMT)
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Amasya University
Chronic Pain, Mental Disorder
Early Detection of Mental Disorders in Adolescents With Chronic Pain: Creation of a Screening Tool for Use by the General Practitioner
This research aims to create a tool for detection of mental health disorders in adolescents with chronic pain. The first part is testing a screening questionnaire and comparing in with existing questionnaires.
- Trial name
- REPERADO (NCT04467229)
- Testing
- Focus group
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Schizophrenia
The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia
The purpose of this study is to determine whether minocycline are effective in the treatment of negative and cognitive symptoms in schizophrenia.
- Trial name
- NCT01493622
- Testing
- minocycline
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Central South University
Psychoses, Substance-Induced
Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids
Ketamine, an FDA approved anesthetic agent, is becoming the sedative/analgesic of choice for emergency sedation in children because it causes deep sedation with minimal respiratory depression in comparison to other available…
- Trial name
- NCT00205712
- Testing
- Ketamine, Dexmedetomidine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Depression, Loneliness
Empower@Home:Connected - Feasibility and Preliminary Effect Study
This single-group trial will evaluate the feasibility and preliminary effect of a novel group-based cognitive behavioral therapy program for older adults with elevated depressive symptoms.
- Conditions
- Depression, Loneliness, Social Isolation, Depressive Disorder
- Trial name
- NCT05732740
- Testing
- Empower@Home:Connected
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Michigan
Overweight, Hyperlipidemia
The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia
This is a 2-year study proposing to examine the effects of aripiprazole on heart health factors such as serum lipids, serum leptin, fasting blood sugar, body weight and blood pressure.
- Conditions
- Overweight, Hyperlipidemia, Cardiovascular Diseases
- Trial name
- NCT00222833
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Bipolar Disorder, Schizophrenia
COMpassion for Psychiatric Disorders And Self-Stigma
People with mental disorders face frequent stigmatizing attitudes and behaviors from others . In response to this, they tend to isolate themselves, with the risk of impeding care and the process of recovery and integration into…
- Conditions
- Bipolar Disorder, Schizophrenia, Depression, Borderline Personality Disorder
- Trial name
- COMPASS (NCT05698589)
- Testing
- Compassion Focused Therapy, Ending Self Stigma
- Where
- 7 sites in France
- Volunteers
- 336 people
- Sponsor
- University Hospital, Strasbourg, France
Suicide, Psychosis
Cognitive Behavioral Suicide Prevention for Psychosis: Aim 2
Investigators will evaluate the feasibility and preliminary effectiveness of modified Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) in comparison to services-as-usual (SAU) in a randomized controlled trial.
- Trial name
- NCT05345184
- Testing
- Cognitive Behavioral Suicide Prevention for psychosis (CBSPp), Services as Usual (SAU)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Michigan
Schizophrenia, Mental Disorder
Evaluation of a Psychoeducation Program for Families Caregivers of Schizophrenic Patients : Randomized Study in Two Arms
The involvement of family members is crucial and improves the prognosis of psychiatric patients and reinforces therapeutic adherence and reduces the frequency of relapses.
- Conditions
- Schizophrenia, Mental Disorder, Educational Problems, Family Relations
- Trial name
- PSYEDUC (NCT03000985)
- Testing
- Psychoeducation
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Charles Perrens, Bordeaux
Psychosis, Schizophrenia
Virtual Reality Avatar Therapy for People Hearing Voices
Hearing voices is probably the worst form of acoustic hallucinations; which can be experienced as severely disturbing and is influenced by diverse factors including the ability of the individual to influence and control the…
- Conditions
- Psychosis, Schizophrenia, Schizo Affective Disorder, Hearing Voices When No One is Talking (Symptom)
- Trial name
- NCT04099940
- Testing
- Virtual Reality Avatar Therapy (VRAT), Assertiveness Training Program (ATP)
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Psychiatric University Hospital, Zurich
Primary Health Care, Mental Disorder
The Effects of Primary Care Behavioral Health in Primary Care in Sweden
The novel multi-professional service delivery model "Primary Care Behavioural Health" (PCBH) has been suggested as an effective way to integrate behavioural health services into routine primary care to overcome the growing…
- Conditions
- Primary Health Care, Mental Disorder, Behavioral Symptoms
- Trial name
- NCT05633940
- Testing
- Implementation of the service delivery model primary care behavioral health
- Where
- Sweden
- Volunteers
- 500 people
- Sponsor
- Region Östergötland
Schizophrenia
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
This is an extension study of A7501013 (P05771/NCT00145496) to further test the efficacy and safety of Asenapine compared with a marketed agent (olanzapine) in the treatment of patients with persistent negative symptoms of…
- Trial name
- NCT00174265
- Testing
- asenapine, olanzapine
- Volunteers
- 196 people
- Sponsor
- Organon and Co
Depression, Psychotic Disorders
Clinical and Biological Characteristics of Psychotic Depression
The primary objective of this study is to investigate the relationships among findings in structural and functional neuroimaging, cognitive testing and HPA (hypothalamic-pituitary-adrenal) axis dysregulation in psychotic…
- Conditions
- Depression, Psychotic Disorders, Depressive Disorder, Major
- Trial name
- NCT00576095
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Stanford University
Schizophrenia, Cognitive Dysfunction
Supportive Psychotherapy as Adjunct to Risperidone for Cognitive Function and Inflammation in Schizophrenia
This study examined whether adding structured supportive psychotherapy to risperidone treatment is more effective than risperidone alone in improving cognitive function and reducing inflammation in patients with schizophrenia.
- Conditions
- Schizophrenia, Cognitive Dysfunction, Inflamation
- Trial name
- SUPPORT-SCZ (NCT07477301)
- Testing
- Structured Supportive Psychotherapy, Risperidone 2 mg
- Where
- Indonesia
- Volunteers
- 46 people
- Sponsor
- Hasanuddin University
Schizophrenia
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.
- Trial name
- NCT02694328
- Testing
- ALKS 3831, Olanzapine
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 561 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia
A study to evaluate the efficacy of 2 fixed-flexible doses of Lu AF11167 on negative symptoms in patients with schizophrenia
- Trial name
- NCT03793712
- Testing
- Lu AF11167 (1-2 mg/day), Lu AF11167 (3-4 mg/day)
- Where
- 53 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 168 people
- Sponsor
- H. Lundbeck A/S